Interventional Cardiovascular Surgery

Cardiac surgery is surgery on the heart or great vessels performed by cardiac surgeons. It is often used to treat complications of ischemic heart disease (for example, with coronary artery bypass grafting) or to treat valvular heart disease from various causes. Cardiac surgeons, interventional cardiologists and imaging specialists typically work together as the Heart Team, in particular in structural heart centres of excellence. In this section, you will find a selection of content in the field of interventional vardiovascular surgery.

View the Interventional CV Surgery editorial team

Read the editorial by F. Maisano and W. Wijns

Filtered By
TOPICS

115 results

When the interventional cardiologist meets the surgeon

18 Nov 2025 – From PCR London Valves 2025

This session highlights collaborative approaches between interventional cardiologists and surgeons in complex valve interventions. It includes cases such as transfemoral valve-in-valve TAVI in bio-Bentall patients with chronic aortic dissection, critical decision-making in life-threatening scenarios, the importance of access choice in TMVR, mechanical leaflet modification of failed...

PARTNER 3 — 7-year follow-up: what it means for low-risk patients

16 Nov 2025 – From PCR London Valves 2025

Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.

They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...

PARTNER 3 — 7-year follow-up: what it means for low-risk patients

PARTNER 3: transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years

14 Nov 2025

At 7 years, low-risk patients affected by severe symptomatic aortic valve stenosis 1:1 randomly treated by SAPIEN 3 TAVI or surgery showed similar clinical outcomes and late valve durability

Igor Belluschi

Reviewer

Igor Belluschi

Reviewer

Salvatore Brugaletta
PARTNER 3: TAVR or SAVR in low-risk patients at 7 years

Percutaneous coronary intervention of native coronary artery versus saphenous vein graft in patients with prior coronary artery bypass graft surgery (PROCTOR)

03 Nov 2025

Kalaivani Mahadevan and Trisha Singh provide their take on the PROCTOR study presented by Ruben de Winter at TCT 2025, in San Francisco.

Kalaivani Mahadevan

Author

Kalaivani Mahadevan
Trish Singh

Author

Trish Singh
PROCTOR: PCI of native coronary artery vs SVGin patients with prior CABG

iFR versus angiography-guided CABG: 3-year results of the iCABG randomised trial

31 Oct 2025

Alex Sticchi provides his take on the iCABG trial presented by Rasa Ordiene at TCT 2025, in San Francisco.

Alessandro Sticchi

Author

Alessandro Sticchi
iFR versus angiography-guided CABG: 3-year results of the iCABG randomized trial

Surgical left atrial appendage occlusion in VHD without AF: OPINION Trial

03 Sep 2025

Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Alessandro Sticchi

Author

Alessandro Sticchi
OPINION Trial: 1-year outcomes

TOP-CABG: the timing of platelet inhibition after coronary artery bypass grafting trial

02 Sep 2025

Jonathan Curio provides his take on TOP-CABG, presented by Xin Yuan at ESC Congress 2025 in Madrid.

Jonathan Curio

Author

Jonathan Curio
TOP-CABG: the timing of platelet inhibition after coronary artery bypass grafting trial

TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome

03 Sep 2025

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Author

Aaysha Cader
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome

Outcomes after CABG compared with FFR-guided PCI in patients presenting with acute coronary syndrome

10 Jun 2025

This prespecified analysis of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME 3) trial examined the impact on cardiovascular outcomes of treatment by CABG versus FFR-guided PCI in patients with three vessel disease (3-VD), stratified by acute (NSTEMI) or chronic coronary syndrome (CCS) presentation.

Ruxandra Sava

Reviewer

Ruxandra Sava
Nicola Ryan

Reviewer

Nicola Ryan
Outcomes after CABG compared with FFR-guided PCI in patients presenting with ACS

2025 Andreas Grüntzig Ethica Award presented to Lars Wallentin and Stefan James on behalf of Swedish cardiovascular registry experts

20 May 2025

The Andreas Grüntzig Ethica Award is traditionally given to those who have contributed in an extraordinary way to the PCR mission, that of serving the needs of patients by sharing knowledge, experience and practice in cardiovascular interventional medicine.

2025 Andreas Grüntzig Ethica Award presented to Lars Wallentin and Stefan James on behalf of Swedish cardiovascular registry experts